Off-label use of anticancer drugs (Q37326851)

19 August 2017

1 reference

title

Off-label use of anticancer drugs (English)

1 reference

19 August 2017

Dominique Levêque

1

1 reference

19 August 2017

1 November 2008

1 reference

Lancet Oncology Commission

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

11

1 reference

19 August 2017

1102-1107

1 reference

Experts weigh in on promotion, prescription of off-label drugs.

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

A literature review on off-label drug use in children

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Reimbursement Policies Constrain the Practice of Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

[Off label drugs and pediatric hematology-oncology practices]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Off-label prescribing in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Off-label prescribing among office-based physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Indian Medical Association wants off-label prescribing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Legal considerations in off-label medication prescribing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

The ethics of off-label use of drugs: oncology pharmacy in Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Off-label use of medicines: consensus recommendations for evaluating appropriateness

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Reform of drug regulation--beyond an independent drug-safety board

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Intraperitoneal chemotherapy comes of age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

"Will weekly work"? Seems to be so....

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Docetaxel administration schedule: from fever to tears? A review of randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Pediatric drug labeling: improving the safety and efficacy of pediatric therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Pharmaceutical reimbursement: an overview.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Reimbursement for cancer treatment: coverage of off-label drug indications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

FDA guidance on off-label promotion and the state of the literature from sponsors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

Current status of development of anticancer agents in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970280-8

7 January 2021

10.1016/S1470-2045(08)70280-8

Identifiers

DOI

1 reference

release_dplqe4wkdrforfyapegv3hury4

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dplqe4wkdrforfyapegv3hury4

24 November 2022

mapped directly with Wikidata item

PubMed ID

19012859

1 reference

PubMed ID

19012859